Back to top
more

Sensus Healthcare (SRTS)

(Delayed Data from NSDQ)

$5.33 USD

5.33
80,520

+0.08 (1.52%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $5.32 -0.01 (-0.19%) 7:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Think Sensus Healthcare (SRTS) Is a Good Investment: Is It?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Sensus Healthcare (SRTS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Sensus Healthcare, Inc. (SRTS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Zacks Equity Research

Sensus Healthcare (SRTS) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Sensus Healthcare (SRTS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Best Momentum Stocks to Buy for August 13th

by Zacks Equity Research

BLBD and SRTS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 13, 2024.

Zacks Equity Research

Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 64.74%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 64.7% upside potential for Sensus Healthcare (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

New Strong Buy Stocks for August 13th

by Zacks Equity Research

BLBD, SRTS, LAKE, MPW and NYT have been added to the Zacks Rank #1 (Strong Buy) List on August 13, 2024.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Sensus Healthcare (SRTS) delivered earnings and revenue surprises of 233.33% and 31.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Benjamin Rains headshot

Buying Great Under-the-Radar Stocks During the August Market Pullback

by Benjamin Rains

Investors who want to buy stocks in August might consider searching for stocks gaining more attention from Wall Street. Today we dive into Sensus Healthcare (SRTS) stock and more.

Zacks Equity Research

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

908 Devices (MASS) delivered earnings and revenue surprises of 5.88% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 25.81% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.25, representing a -1.88% change from its previous close.

Zacks Equity Research

Hologic (HOLX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 3.92% and 1.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Sensus Healthcare (SRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Recent Price Trend in Sensus Healthcare (SRTS) is Your Friend, Here's Why

by Zacks Equity Research

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $6.42, moving -0.47% from the previous trading session.

Shrabana Mukherjee headshot

3 Stocks in Focus as New Analysts Initiate Coverage

by Shrabana Mukherjee

The recent surge in analyst coverage for stocks such as BrightSphere (BSIG), Sensus Healthcare (SRTS) and ServisFirst (SFBS) indicates the potential for significant price appreciation in the near term.

Zacks Equity Research

Sensus Healthcare (SRTS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Sensus Healthcare (SRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) closed at $5.99 in the latest trading session, marking a -0.66% move from the prior day.

Zacks Equity Research

Sensus Healthcare (SRTS) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.87, marking a -1.81% move from the previous day.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) closed at $5.22 in the latest trading session, marking a -1.51% move from the prior day.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) concluded the recent trading session at $5.48, signifying a -0.54% move from its prior day's close.